ALDX Stock Price, Aldeyra Therapeutics Inc Quote, Chart

Market Summary

USD3.70-0.07

Market Closed

-1.86%

ALDX Alerts

1 major insider buys recently.

ALDX Stock Price

View Fullscreen

ALDX RSI Chart

ALDX Valuation

Market Cap

219.8M

Price/Earnings (Trailing)

-7.33

EV/EBITDA

-2.66

Price/Free Cashflow

-7.12

MarketCap/EBT

-4.33

ALDX Price/Sales (Trailing)

ALDX Profitability

Return on Equity

-26.46%

Return on Assets

-21.24%

Free Cashflow Yield

-14.04%

ALDX Fundamentals

ALDX Earnings

Earnings (TTM)

-30.0M

Earnings Growth (Yr)

48.24%

Earnings Growth (Qtr)

-70.04%

Breaking Down ALDX Revenue

Last 7 days

-10.2%

Last 30 days

-12.9%

Last 90 days

16.4%

Trailing 12 Months

-63.6%

How does ALDX drawdown profile look like?

ALDX Financial Health

Current Ratio

6.5

ALDX Investor Care

Shares Dilution (1Y)

1.43%

Diluted EPS (TTM)

-0.78

Tracking the Latest Insider Buys and Sells of Aldeyra Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	perceptive advisors llc	bought	178,755	4.74	37,712	-
Apr 04, 2024	perceptive advisors llc	bought	655,112	4.67	140,281	-
Apr 03, 2024	perceptive advisors llc	bought	1,267,270	4.09	309,847	-
Apr 02, 2024	perceptive advisors llc	bought	640,015	3.44	186,051	-
Apr 01, 2024	perceptive advisors llc	bought	27,215	3.25	8,374	-
Mar 12, 2024	brady todd c	sold	-260,238	3.05	-85,324	president and ceo
Mar 12, 2024	machatha stephen	sold	-36,503	3.164	-11,537	chief development officer
Mar 11, 2024	machatha stephen	sold	-62,102	3.4064	-18,231	chief development officer
Mar 11, 2024	greenberg bruce	sold	-44,967	3.4064	-13,201	see remarks

Which funds bought or sold ALDX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	VANGUARD GROUP INC	reduced	-1.49	-1,133,980	12,651,900	-%
May 10, 2024	BlackRock Inc.	reduced	-3.5	-1,215,740	10,826,300	-%
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-2.01	-2,216	23,217	-%
May 10, 2024	CORNERCAP INVESTMENT COUNSEL INC	unchanged	-	-14,785	201,435	0.03%
May 10, 2024	LPL Financial LLC	added	8.27	571	66,636	-%
May 10, 2024	CITIGROUP INC	added	21.41	2,957	25,513	-%
May 10, 2024	ACADIAN ASSET MANAGEMENT LLC	added	106	710,000	1,478,000	-%
May 10, 2024	GROUP ONE TRADING, L.P.	reduced	-53.51	-25,878	19,770	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	reduced	-15.06	-761,196	2,884,830	-%
May 10, 2024	JOHNSON & JOHNSON	unchanged	-	-71,920	979,918	0.02%

Are Funds Buying or Selling ALDX?

Are funds buying ALDX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALDX

No. of Funds

ALDX Alerts

1 major insider buys recently.

Unveiling Aldeyra Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	perceptive advisors llc	14.6%	8,593,586	SC 13G/A
Feb 13, 2024	vanguard group inc	6.68%	3,927,597	SC 13G
Jan 29, 2024	blackrock inc.	5.8%	3,430,774	SC 13G
Oct 19, 2023	perceptive advisors llc	14.7%	8,593,586	SC 13G/A
Oct 04, 2023	knoll capital management, llc	6.1%	3,595,916	SC 13G
Feb 14, 2023	perceptive advisors llc	19.4%	11,350,085	SC 13G/A
Feb 03, 2023	state street corp	0.30%	173,281	SC 13G/A
Jul 08, 2022	blackrock inc.	1.7%	974,947	SC 13G
Feb 14, 2022	perceptive advisors llc	17.0%	9,903,879	SC 13G/A
Feb 09, 2022	state street corp	5.31%	3,082,352	SC 13G

Recent SEC filings of Aldeyra Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
Apr 25, 2024	8-K	Current Report
Apr 24, 2024	EFFECT	EFFECT
Apr 22, 2024	ARS	ARS
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	DEFA14A	DEFA14A
Apr 17, 2024	4/A	Insider Trading
Apr 17, 2024	4/A	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading

Peers (Alternatives to Aldeyra Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Aldeyra Therapeutics Inc News

Latest updates

Aldeyra Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-4.7%	141	148	147	156	168	181	190	201	223	233	247	256	147	83.00	88.00	72.00	63.00	76.00	77.00	74.00	88.00
Current Assets	-4.7%	141	148	147	155	168	181	189	201	222	233	247	256	147	83.00	88.00	71.00	63.00	75.00	77.00	73.00	87.00
Cash Equivalents	-28.2%	102	143	143	152	165	144	129	121	159	230	241	250	138	78.00	86.00	61.00	39.00	44.00	52.00	39.00	44.00
Net PPE	-29.2%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-2.3%	28.00	29.00	24.00	26.00	31.00	30.00	27.00	27.00	32.00	27.00	28.00	23.00	21.00	24.00	19.00	19.00	20.00	27.00	27.00	7.00	10.00
Current Liabilities	-2.6%	22.00	22.00	22.00	16.00	16.00	15.00	24.00	16.00	16.00	12.00	12.00	7.00	11.00	12.00	6.00	5.00	5.00	13.00	12.00	6.00	9.00
Long Term Debt	-	-	-	3.00	10.00	15.00	15.00	3.00	11.00	16.00	16.00	15.00	15.00	10.00	11.00	13.00	14.00	15.00	15.00	14.00	-	-
LT Debt, Current	0.4%	15.00	15.00	13.00	6.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	3.00	10.00	15.00	15.00	3.00	11.00	16.00	16.00	15.00	15.00	10.00	11.00	13.00	14.00	15.00	15.00	14.00	-	-
Shareholder's Equity	-5.3%	113	120	123	130	137	151	162	174	191	206	220	234	126	60.00	69.00	53.00	43.00	48.00	51.00	67.00	78.00
Retained Earnings	-2.0%	-402	-394	-389	-381	-372	-356	-343	-329	-311	-294	-278	-263	-248	-236	-225	-216	-209	-199	-186	-167	-154
Additional Paid-In Capital	0.3%	516	514	512	511	510	508	506	504	502	500	499	497	374	296	295	270	253	247	237	235	233
Shares Outstanding	0.4%	59.00	59.00	59.00	59.00	59.00	59.00	58.00	58.00	58.00	58.00	53.00	54.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	483	-	-	-	228	-	-	-	649	-	-	-	128	-	-	-	153	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-2092.8%	-9,972	500	-8,024	-13,357	-9,443	-11,231	-12,574	-19,958	-12,873	-11,577	-8,434	-9,072	-13,471	-8,317	-6,237	-7,579	-15,359	-11,226	-8,315	-12,810	-12,631
Share Based Compensation	293.5%	1,549	-800	789	1,574	4,190	2,821	2,237	1,294	1,937	984	1,418	2,324	2,382	1,630	1,757	1,742	1,954	1,949	2,153	2,095	1,886
Cashflow From Investing	-Infinity%	-30,376	-	-	-	30,000	27,000	19,016	-17,938	-58,031	-	-	-	-7.81	-	5,500	17,300	6,224	-4,285	5,676	7,922	9,164
Cashflow From Financing	101.8%	18.00	-1,012	-315	5.00	53.00	-	1,197	-	23.00	-	64.00	120,369	74,064	1*	26,224	12,425	3,253	8,333	14,844	-9.14	408

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ALDX Income Statement

2024-03-31

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 6,183,508	$ 11,235,861
General and administrative	3,210,357	5,567,416
Loss from operations	(9,393,865)	(16,803,277)
Other income (expense):
Interest income	1,810,269	1,678,885
Interest expense	(498,526)	(491,287)
Total other income, net	1,311,743	1,187,598
Net loss	$ (8,082,122)	$ (15,615,679)
Net loss per share - basic	$ (0.14)	$ (0.27)
Net loss per share - diluted	$ (0.14)	$ (0.27)
Weighted average common shares outstanding - basic	59,414,489	58,791,603
Weighted average common shares outstanding - diluted	59,414,489	58,791,603

ALDX Balance Sheet

2024-03-31

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 52,491,900	$ 142,823,016
Cash equivalent - reverse repurchase agreements	50,000,000	0
Marketable securities	30,545,450	0
Prepaid expenses and other current assets	7,808,596	4,987,317
Total current assets	140,845,946	147,810,333
Right-of-use assets	451,867	510,814
Fixed assets, net	4,079	5,764
Total assets	141,301,892	148,326,911
Current liabilities:
Accounts payable	280,299	1,338,057
Accrued expenses	5,944,419	5,536,464
Current portion of debt	15,204,698	15,146,546
Operating lease liabilities	247,021	239,183
Total current liabilities	21,676,437	22,260,250
Long-term debt, net of current portion	0	0
Deferred collaboration revenue, long term	6,000,000	6,000,000
Operating lease liabilities, long-term	206,014	271,631
Total liabilities	27,882,451	28,531,881
Commitments and contingencies (Notes 13, 14, and 15)
Stockholders' equity:
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding	0	0
Common stock, voting, $0.001 par value; 150,000,000 authorized and 59,414,489 and 59,195,951 shares issued and outstanding, respectively	59,415	59,196
Additional paid-in capital	515,704,325	513,994,982
Accumulated other comprehensive loss	(3,029)	0
Accumulated deficit	(402,341,270)	(394,259,148)
Total stockholders’ equity	113,419,441	119,795,030
Total liabilities and stockholders’ equity	$ 141,301,892	$ 148,326,911

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

CEO	Dr. Todd C. Brady M.D., Ph.D.
WEBSITE	aldeyra.com
INDUSTRY	Biotechnology
EMPLOYEES	15

Aldeyra Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aldeyra Therapeutics Inc? What does ALDX stand for in stocks?

ALDX is the stock ticker symbol of Aldeyra Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aldeyra Therapeutics Inc (ALDX)?

As of Mon May 13 2024, market cap of Aldeyra Therapeutics Inc is 219.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALDX stock?

You can check ALDX's fair value in chart for subscribers.

What is the fair value of ALDX stock?

You can check ALDX's fair value in chart for subscribers. The fair value of Aldeyra Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aldeyra Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aldeyra Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ALDX is over valued or under valued. Whether Aldeyra Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aldeyra Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALDX.

What is 5 year return on Aldeyra Therapeutics Inc's stock?

In the past 10 years, Aldeyra Therapeutics Inc has provided -0.065 (multiply by 100 for percentage) rate of return.